Key result
Recent non-rheumatic AF therapies lack robust validation in rheumatic valvular heart disease.
Why the study?
Treatment modalities for non-rheumatic atrial fibrillation have not been extensively validated in patients with rheumatic valvular heart disease.
Non-rheumatic AF therapies lack extensive validation in rheumatic valvular disease; leaves open whether they can be directly applied.
PURPOSE OF REVIEW: Atrial fibrillation in patients with rheumatic valvular heart disease results in significant morbidity and possibly mortality. RECENT DEVELOPMENTS: The recent advances in treatment options for non-rheumatic atrial fibrillation have widened its scope of management. These treatment modalities have not been extensively validated in rheumatic valvular heart disease. SUMMARY: A review and comparison of the available data in atrial fibrillation and rheumatic valvular heart disease vis-à-vis non-rheumatic atrial fibrillation is presented.
No takes yet. Share an insight, caveat, or question.
Amit M. Vora (2005) conducted a review in Atrial fibrillation in rheumatic valvular heart disease. Treatment modalities for atrial fibrillation was evaluated. Recent advances in treatment options for non-rheumatic atrial fibrillation have not been extensively validated in patients with rheumatic valvular heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: